Revolo Biotherapeutics was founded with one specific goal in mind: to benefit people living with autoimmune and allergic diseases by creating novel, life-changing therapeutics that induce long-term remission. They have been working towards this goal as they develop ‘1104, one of the company’s two drug candidates. ‘1104 is being developed specifically for people with allergic disease, such as allergen sensitivity or eosinophilic esophagitis (EoE). In fact, shares a recent news release, a Phase 2a study evaluating ‘1104 was recently completed.

60 participants with moderate-to-severe allergic disease (seasonal allergic rhinitis) enrolled in the randomized, double-blind trial. Over a 12-week period, study participants received either ‘1104 or a placebo. Revolo Biotherapeutics explains that ‘1104:

was derived from a natural immune-regulatory protein, Mycobacterium tuberculosis Chaperonin 60.1, involved in resetting the immune system. It may provide long-term remission for many allergic diseases.

Outside of this study, researchers have also performed a similar Phase 2a study on ‘1104 for EoE. Data from both studies should be available in the second quarter (Q2) of 2023. So far, the data has suggested that ‘1104 is effective in reducing inflammation (a hallmark of certain autoimmune and allergic conditions).

Moving forward, Revolo Biotherapeutics hopes to continue developing ‘1104 for EoE and allergic disease; the company also hopes to launch a study into ‘1104 for patients living with certain food allergies.

About Eosinophilic Esophagitis (EoE)

Even though the above study centered more around seasonal allergic rhinitis than EoE, ‘1104 is a potential therapeutic option for patients with EoE. Since Patient Worthy works so closely with the EoE community, we also wanted to highlight some EoE facts here.

So what is eosinophilic esophagitis? This chronic, immune-mediated digestive system disorder is characterized by the presence of high amounts of eosinophils (a type of white blood cell) in the esophagus. Normally, eosinophils play a role in:

• How our immune system responds to infection
• The way our immune system is regulated
• Allergic response

Seeing a high amount of eosinophils in a certain area (such as the esophagus) is typical of allergic diseases. In people with EoE, eosinophils accumulate in the esophagus and are believed to be due to immune hypersensitivity to certain foods or allergens. An estimated 1 in every 2,000 people has EoE. Symptoms, and the age in which they appear, may vary between individuals. Potential symptoms may include:

• Dysphagia (difficulty swallowing)
• Nausea and vomiting
• Abdominal pain
• Appetite loss
• Malnutrition
• Failure to thrive (in infants)
• Poor growth
• Unintentional weight loss
• Food impaction (in the throat)
• Asthma, eczema, or other allergic conditions

Current treatment options include dietary changes, proton pump inhibitor therapy, and Dupixent.